达格列净预防择期心脏手术后急性肾损伤的随机临床试验
该多中心双盲安慰剂对照随机临床试验在荷兰7家中心纳入784例择期心脏手术成人患者,评估术前1天开始口服达格列净10 mg(共4剂)对术后7天急性肾损伤(AKI)发生率的影响。
要点
- 择期心脏手术患者术前1天至术后第2天口服达格列净10 mg共4剂,术后7天AKI发生率显著低于安慰剂。
- 两组房颤(45% vs 45%)与再次手术(11% vs 10%)发生率相近。
核心结论
- 择期心脏手术患者术前1天开始服用达格列净10 mg共4剂,可降低术后7天AKI发生率。
研究设计与样本
- 多中心、双盲、安慰剂对照随机临床试验,在荷兰2家学术医学中心和5家非学术医院开展。
- 纳入784例择期心脏手术成人患者,按1:1随机接受达格列净10 mg口服(n=392)或安慰剂(n=392),术前1天开始每日一次至术后第2天,共4剂。
- 778例(99%)完成随访检测,中位年龄68岁(IQR 61-74),76%男性,97%白人,中位BMI 27(IQR 25-30),中位eGFR 80 mL/min/1.73 m2(IQR 67-89)。
主要发现
- 最常见不良事件为房颤和再次手术,房颤发生率两组均为45%(176/392),再次手术发生率分别为11%(43/392)与10%(39/392)。
关键数值与推荐
- AKI定义依据KDIGO标准:术后48小时内血清肌酐升高至少0.3 mg/dL(26.5 µmol/L),或术后7天内肌酐升高1.5倍,或尿量少于0.5 mL/kg/h持续6至12小时。
- 主要结局为术后7天内AKI发生率的组间差异。
临床怎么用
- 对于择期心脏手术成人患者,可考虑术前1天开始短期口服达格列净10 mg每日一次至术后第2天,以降低术后AKI风险。
- 用药期间需关注房颤和再次手术等不良事件,但本试验中两组发生率相近。
局限性
- 研究仅纳入荷兰7家中心择期心脏手术成人患者,外推性需谨慎。
- 随访周期为术后7天,未评估更长时期肾功能结局。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Two percent to 50% of patients undergoing elective cardiac surgery experience acute kidney injury (AKI) postoperatively. Medications to prevent AKI after elective cardiac surgery have not been identified. OBJECTIVE: In patients undergoing elective cardiac surgery, to evaluate whether initiating dapagliflozin 1 day prior to surgery reduces the incidence of AKI at 7 days after cardiac surgery, compared with placebo. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled randomized clinical trial conducted at 2 academic medical centers and 5 nonacademic hospitals in the Netherlands. Eligible participants were adults undergoing elective cardiac surgery. Enrollment occurred between June 8, 2023, and January 27, 2025. Final follow-up occurred May 16, 2025. INTERVENTION: Patients were randomized 1:1 to receive either dapagliflozin (10 mg orally; n = 392) or placebo once daily (n = 392), beginning on the day before surgery and continuing through the second postoperative day (total of 4 doses). MAIN OUTCOME AND MEASURE: The primary outcome was the between-group difference in AKI (defined as an increase in serum creatinine level by at least 0.3 mg/dL [26.5 µmol/L] within 48 hours after surgery, a 1.5-fold creatinine increase within 7 days of surgery, or urine output less than 0.5 mL/kg/h for 6 to 12 hours according to Kidney Disease: Improving Global Outcomes criteria) during the first 7 postoperative days. RESULTS: Of 784 participants enrolled, 778 (99%) completed follow-up testing (median age, 68 [61-74] years; 76% male; 97% White; median body mass index, 27 [IQR, 25-30]; and median estimated glomerular filtration rate, 80 [IQR, 67-89] mL/min/1.73 m2). Compared with placebo, dapagliflozin reduced the incidence of AKI (28% vs 52%; relative risk, 0.54 [95% CI, 0.45-0.65]; P < .001) over 7-day follow-up after surgery. Atrial fibrillation and reoperation were the most frequent adverse events. The incidence of atrial fibrillation was 45% (176/392) in the dapagliflozin group vs 45% (176/392) in the placebo group, and the incidence of reoperation was 11% (43/392) vs 10% (39/392), respectively. CONCLUSIONS AND RELEVANCE: In patients undergoing elective cardiac surgery, 4 doses of dapagliflozin, beginning the day before surgery, reduced the incidence of AKI during the 7-day postoperative period. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05590143.
引用
- Oosterom-Eijmael MJP, Hulst AH, de Oliveira NPM, et al. Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial. JAMA. 2026. PMID: 42530910. doi:10.1001/jama.2026.9268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。